ArticleFrontiers in endocrinology2025
Case Report: Resolution of complete heart block following vitamin D supplementation in a child with Graves disease.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes an 11-year-old male with Graves disease and pre-existing Mobitz type 1 second-degree atrioventricular (AV) block that progressed to complete heart block (CHB) one month prior to his diagnosis of Graves disease. He presented at age 9 years (January 2023) with weight loss, heat intolerance, and excessive sweating. Laboratory testing revealed: thyroid stimulating hormone (TSH) <0.01 uIU/mL, free thyroxine (FT4) 4.8 ng/dL, total thyroxine (T4) 16.7 µg/dL, and total triiodothyronine (T3) 334 ng/dL. He was treated with methimazole and was biochemically euthyroid within one month of treatment. Despite becoming euthyroid, the CHB persisted. By April of 2023, his cardiologist recommended the implantation of a pacemaker, however the family opted for continued monitoring instead. Following his mother's research into potential benefits of vitamin D in autoimmune thyroid disease, vitamin D3 supplementation 2500 IU daily was initiated in late October 2023. Three months later, his nighttime bradycardia resolved. A 12-lead ECG in April 2024 confirmed the resolution of CHB to first-degree AV block. No additional medications were used to treat his cardiac condition. Patient remained stable with first-degree heart block while euthyroid on low dose methimazole. He continued vitamin D supplementation at 2000 IU daily. Peak TSH receptor antibody (TSHRab) and thyroid-stimulating immunoglobulin (TSI) values decreased following vitamin D3 initiation. Several proposed mechanisms may explain this observation, including vitamin D's immunomodulatory effects on Graves disease, its cardioprotective properties, and its potential synergistic effect with methimazole in achieving better thyroid control. This case highlights a potential association between vitamin D supplementation and improved AV block in a pediatric patient with Graves disease, warranting further investigation into vitamin D's role in managing cardiac manifestations of autoimmune thyroid disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.